Cabotegravir And Rilpivirine: Efficacy and Safety Study (CARES) is research project that aims to make taking medication easier for people living with HIV in sub-Saharan Africa. Many people on combination anti-retroviral therapy (cART) must take many pills each day to maintain their health and well-being. CARES offers an alternative: injectable medication taken 6 times per year. Because this regimen offers the benefit of reduced dosing from daily pills to injections every 2 months, the study is expected to demonstrate whether or not this could have a positive impact on the patient’s quality-of-life, improve adherence to treatment, improve engagement in care and reduce the stigma associated with the daily use of oral pills.
It is a randomised clinical trial being done at eight sites in three African countries: Uganda, Kenya, and South Africa. Participants who are eligible for the trial are randomly allocated to either stay on the oral tablet form of their HIV treatment or to switch to two monthly injections of the HIV medicines Cabotegravir and Rilpivirine (CAB + RPV LA).
Both groups are followed up for a total of 24 months, with periodic assessments to determine how effective the medicines are working and if there are any safety concerns. Specifically, we monitor and shall compare the following between the two groups.
In addition to these, we shall interview participants and health workers to determine their perspectives on the use of these injectable medicines
The trial is following up on 512 participants, who were recruited at the 8 trial sites which are showcased in this website.